Serebryany honored for work on cataracts
Growing up in Russia, Evgeny “Eugene” Serebryany mostly enjoyed humanities-related courses. He developed new interests after he moved to the U.S. as a teenager and faced a language barrier.
At his Massachusetts high school, Serebryany began to translate Russian poetry, which he still does, and he started to embrace science.
Evgeny Serebryany was approved for a green card in time to receive the NIH award that funds most of his research into new treatments for cataracts.
“Experimental science offered a way to contribute to advancement of knowledge in a very concrete way,” he said.
His path wasn’t always easy. “Immigration status has been the biggest roadblock,” he said.
As an international student, he wasn’t eligible for federal grants or loans for college, and his family couldn’t afford the tuition. Yale University offered him full financial aid from endowment funds, and he earned a bachelor’s degree in molecular biophysics and biochemistry while doing research in the laboratory of .
Federal training grants also cannot fund graduate students who lack permanent U.S. residency. The Massachusetts Institute of Technology granted Serebryany a private fellowship, and he completed his Ph.D. in biochemistry with . He is now a postdoctoral fellow in research group at Harvard.
Serebryany said he is grateful to both Yale and MIT for the education he received “on their own dime.”
As a postdoc, he petitioned the U.S. government for a green card based on exceptional scientific ability in the national interest. His request was approved in February 2018, and he gained permanent resident status in time to receive the National Institutes of Health National Research Service Award, which now funds most of his research.
“I couldn’t travel abroad. Now I can,” he said. “But beyond the funding and travel restrictions, just the fear of someday not being able to extend my string of temporary statuses … and then having to leave or get deported, made it that much harder to focus on the research.
“The sense of freedom and security that a green card gives, though not complete, is priceless.”
Disulfide bonds offer new insights into cataracts
Cataracts impair vision by clouding the eye’s lens, mostly in older people. Most proteins in the lens belong to the crystallin family; as we age, the crystallin proteins can start to clump together, causing the lens to scatter light and become less transparent.
Serebryany and his colleagues used biochemical approaches including mass spectrometry and mutational analysis to develop new mechanistic insights into disulfide bond formation and exchange in crystallins, which led them to propose a “redox hot potato” competition model; under physiological conditions, stable gamma-crystallin molecules in the lens continually exchange disulfides. However, if a stable molecule passes the disulfide to a structurally unstable one, the latter becomes trapped in a structure prone to aggregation, which results in light scattering, the hallmark of cataracts.
Cataracts can be addressed in two ways. When prescription eyeglasses become ineffective, patients are left with the option of surgery, which is effective but expensive and not available to everyone. Cataracts remain the world’s leading cause of blindness. The work of Serebryany and his colleagues may pave the way to lower-cost therapeutic treatment.
Read his prize-winning paper .
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles
From dust to discovery
From makeshift classrooms in Uganda to postdoctoral research in Chicago, MOSAIC scholar Elizabeth Kaweesa builds a legacy in women鈥檚 health.
Fliesler wins scientific and ethical awards
He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.
Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥� to help the patients who need it most.
Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥� and just getting started.
91影库members recognized as Allen investigators
Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.
AI can be an asset, 91影库educators say
Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.